Michelle Dipp, 36, reflects biotech’s next generation
OvaScience is developing a treatment to improve the odds for women to get pregnant through in vitro fertilization or IVF. The promise of its biotechnology has helped make OvaScience one of the hottest young companies on the Cambridge biotech scene. OvaScience has raised $40 million this year alone and hopes to land on the Nasdaq stock exchange by early next year. If it does, Michelle Dipp, at 36, would be among the youngest CEOs of a public company in Massachusetts.